drugset / Trial / NCT07231952
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Phase 2
Recruiting
40 enrolled
Memorial Sloan Kettering Cancer Center
AbbVie · collabEli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
Timeline
- Start
- 2025-11-11
- Primary completion
- 2028-04-11
- Completion
- 2028-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirtobrutinib | Other / unclassified | — | Oral |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |